Evidence map›Paper›PMID 38411756›Full record

ArticleAnnals of intensive care2024

Immediate vs. culture-initiated antibiotic therapy in suspected non-severe ventilator-associated pneumonia: a before-after study (DELAVAP).

Maëlle Martin, Solène Forveille, Jean-Baptiste Lascarrou, Amélie Seguin, Emmanuel Canet, Jérémie Lemarié, Maïté Agbakou, Luc Desmedt, Gauthier Blonz, Olivier Zambon and 3 more

Open access · goldAbstract read
In one paragraph

Article in Annals of intensive care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Maëlle MartinNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France. maelle.martin@chu-nantes.fr.ORCID http://orcid.org/0000-0002-0365-4558
Solène ForveilleNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Jean-Baptiste LascarrouNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Amélie SeguinNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Emmanuel CanetNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Jérémie LemariéNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Maïté AgbakouNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Luc DesmedtNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Gauthier BlonzNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Olivier ZambonNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Stéphane CorvecNantes Université, CHU Nantes, Institut de Biologie des Hôpitaux de Nantes, Service de Bactériologie Et Des Contrôles Microbiologiques, Nantes, France.
Aurélie Le ThuautNantes Université, CHU Nantes, Plateforme de méthodologie et biostatistique, Direction de la recherche et de l'innovation, Nantes, France.
Jean ReignierNantes Université, CHU Nantes, Médecine Intensive Réanimation, Nantes, France.
Centre Hospitalier Universitaire de Nantes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVentilator-associated pneumonia (VAP) is the leading nosocomial infection in critical care and is associated with adverse outcomes. When VAP is suspected, starting antibiotic therapy (AT) immediately after pulmonary sampling may expose uninfected patients to unnecessary treatment, whereas waiting for bacteriological confirmation may delay AT in infected patients. As no robust data exist to choose between these strategies, the decision must balance the pre-test diagnostic probability, clinical severity, and risk of antimicrobial resistance. The objective of this study in patients with suspected non-severe VAP was to compare immediate AT started after sampling to conservative AT upon receipt of positive microbiological results. The outcomes were antibiotic sparing, AT suitability, and patient outcomes.

methodsThis single-center, before-after study included consecutive patients who underwent distal respiratory sampling for a first suspected non-severe VAP episode (no shock requiring vasopressor therapy or severe acute respiratory distress syndrome). AT was started immediately after sampling in 2019 and upon culture positivity in 2022 (conservative strategy). The primary outcome was the number of days alive without AT by day 28. The secondary outcomes were mechanical ventilation duration, day-28 mortality, and AT suitability (active necessary AT or spared AT).

resultsThe immediate and conservative strategies were applied in 44 and 43 patients, respectively. Conservative and immediate AT were associated with similar days alive without AT (median [interquartile range], 18.0 [0-21.0] vs. 16.0 [0-20.0], p = 0.50) and without broad-spectrum AT (p = 0.53) by day 28. AT was more often suitable in the conservative group (88.4% vs. 63.6%, p = 0.01), in which 27.9% of patients received no AT at all. No significant differences were found for mechanical ventilation duration (median [95%CI], 9.0 [6-19] vs. 9.0 [6-24] days, p = 0.65) or day-28 mortality (hazard ratio [95%CI], 0.85 [0.4-2.0], p = 0.71).

conclusionIn patients with suspected non-severe VAP, waiting for microbiological confirmation was not associated with antibiotic sparing, compared to immediate AT. This result may be ascribable to low statistical power. AT suitability was better with the conservative strategy. None of the safety outcomes differed between groups. These findings would seem to allow a large, randomized trial comparing immediate and conservative AT strategies.

Indexed as

Antibiotic stewardshipAntibiotic therapyCritical careVentilator-associated pneumonia

Identifiers

PMID38411756
PMCPMC10897643
OpenAlexW4392190708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.